Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
President Donald Trump’s administration is reviewing the Common Rule revisions as part of a routine process but hasn’t flagged the human research regulations for any changes, a key regulatory official said.
President Barack Obama’s administration pushed through the first-ever revision of the Common Rule on its last day in office. Top officials in the Department of Health and Human Services under Trump are reviewing all so-called midnight rules issued during the final weeks of the previous administration, including the Common Rule.
The 543-page final rule released Jan. 19 culminates a multi-year—and at times controversial—effort to rewrite the regulations that protect research subjects from undue harm. Once effective, these changes will impact nearly 20 federal agencies, along with the universities and other institutions that receive billions of dollars in federal research grants.
“I want to make it clear, there is no implication that anybody has any particular reason to be concerned about this rule in any way at all,” Jerry Menikoff, director of the HHS Office for Human Research Protections, told an HHS advisory committee May 25. “We have not heard anything about specific changes to be made.”
If anything, he said, the HHS may decide to push back the rule’s Jan. 19, 2018, effective date to give research institutions more time to comply with the changes.
But pushing back an effective date could take some time. Menikoff said he expects all the federal agencies that have agreed to follow the Common Rule also would have to sign off on any changes to the effective date.
The regulatory review has put the OHRP in a holding pattern in moving forward on the new rule. The effective date was set to give institutions a year to come into compliance with all but one of the new requirements. But now almost half that time has lapsed.
Holly Fernandez Lynch, a member of the HHS Secretary’s Advisory Committee on Human Research Protections and a bioethicist at the University of Pennsylvania, told Menikoff information about time frames would be helpful.
“The community is trying to figure out the extent to which they should start shifting systems over and making changes,” she said.
Menikoff replied, “We will not hesitate at all to get the information out there immediately, once we have an answer in terms of what the time frame is.”
The goal throughout the process of revising the Common Rule has been to reduce administrative burdens, “and I think it’s true of the new administration too,” Menikoff said.
The first-ever update to the Common Rule accounts for the shift away from a single-lab, single-site model for research in 1991 and toward a global research enterprise incorporating rapidly advancing technologies in mobile health and genomics.
The final rule requires shorter, clearer informed consent forms that apply a “reasonable person standard” to put the most important information at the top. This new requirement addresses concerns that informed consent has evolved into use of lengthy documents designed to protect the research institution, instead of protecting the subject.
The final rule also allows for broad consent—authorization to use someone’s data or biospecimen for unknown, future research—as an alternative to seeking institutional review board approval to waive the consent requirement. As under the current rule, researchers still won’t have to obtain consent for studies on unidentified stored data or biospecimens.
There are also new exemption categories designed to allow IRBs to spend more time reviewing riskier studies, and review boards can skip annual review of studies that pose minimal risk and were approved under an expedited process.
The final rule also requires studies that take place in multiple locations to use the same IRB. But this provision doesn’t take effect until 2020 out of a recognition of the complexity involved in its implementation.
To contact the reporter on this story: Jeannie Baumann in Washington at email@example.com
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)